MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

Начало・Списък с акции・SCYNEXIS Inc

SCYNEXIS Inc

Затворен

1.01 1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

1.05

Ключови измерители
By Trading Economics
Приходи	21M 12M
Продажби	18M 19M
Марж на печалбата	65.741
Служители	18
EBITDA	11M 11M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+246.53% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	9.5M 41M
Предишно отваряне	0.01
Предишно затваряне	1.01

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

0.9307 / 0.9907 Подкрепа & съпротива

SCYNEXIS Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.04.2026 г., 23:36 ч. UTC

Придобивния, сливания и поглъщания

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14.04.2026 г., 23:24 ч. UTC

Горещи акции

Stocks to Watch: Gloo, Broadcom, GitLab

14.04.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14.04.2026 г., 21:32 ч. UTC

Значими двигатели на пазара

GitLab Shares Rise on Expanded Google Cloud Collaboration

14.04.2026 г., 23:54 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Technical Correction -- Market Talk

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14.04.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14.04.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14.04.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14.04.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14.04.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14.04.2026 г., 22:14 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14.04.2026 г., 22:13 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14.04.2026 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14.04.2026 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14.04.2026 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

14.04.2026 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14.04.2026 г., 20:32 ч. UTC

Горещи акции

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14.04.2026 г., 19:59 ч. UTC

Придобивния, сливания и поглъщания

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14.04.2026 г., 19:38 ч. UTC

Печалби

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14.04.2026 г., 19:27 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14.04.2026 г., 19:21 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14.04.2026 г., 19:09 ч. UTC

Придобивния, сливания и поглъщания

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14.04.2026 г., 18:30 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.04.2026 г., 18:30 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

SCYNEXIS Inc Прогноза

Ценова цел

By TipRanks

246.53% нагоре

12-месечна прогноза

Среден 3.5 USD 246.53%

Висок 4 USD

Нисък 3 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за SCYNEXIS Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на SCYNEXIS Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.9307 / 0.9907Подкрепа & съпротива

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.